TNFRSF1B and neoplasm: observed the effective anti‐tumor activity of TNFR2 antibodies and found that TNFR2 is highly expressed in Tregs in the TME but not in other Treg cells in vivo,[107] indicating that TNFR2 inhibition is promising tumor‐specific antitumor strategy that does not induce strong autoimmunity.